GUD Knight Therapeutics Inc
- 5.270
- +0.050+0.96%
Knight Therapeutics Inc News
Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript Summary
Knight Therapeutics Inc (KHTRF) Q3 2024 Earnings Call Highlights: Revenue Growth Amidst Margin ...
Express News | Knight Therapeutics Announces Approval of Minjuvi® (Tafasitamab) in Mexico
Knight Therapeutics Announces Approval of Minjuvi (Tafasitamab) in Mexico
Knight Therapeutics Inc. Places No. 397 on The Globe and Mail's Sixth Annual Ranking of Canada's Top Growing Companies
Knight Therapeutics Inc. Just Missed Earnings; Here's What Analysts Are Forecasting Now
Earnings Flash: Knight Therapeutics Q2 Revenue $95.5 Million, Up 6% From 2023
Knight Therapeutics Brief: Delivered Record Revenues of $95.573 Million, an Increase of 6% Over the Same Period in Prior Year
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call
Knight Therapeutics Inc. (TSE:GUD) Stock Most Popular Amongst Individual Investors Who Own 40%, While Private Companies Hold 25%
Knight Therapeutics Inc: INTERIM MDA FR
Knight Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT FR
Earnings Call Summary | KNIGHT THERAPEUTICS INC(KHTRF.US) Q1 2024 Earnings Conference
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
Knight Therapeutics Inc: INTERIM MDA EN
Knight Therapeutics Inc: INTERIM FINANCIAL STATEMENTSREPORT EN
Knight Therapeutics Brief: Entering Into Exclusive Supply and Distribution Agreement With Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America
Knight Therapeutics Reports First Quarter 2024 Results
Knight Therapeutics Inc. Announces Voting Results From the Annual General Meeting
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
No Data